Elizabeth Leef Jacobson, M.D.

Allergy and Immunology


Smith KA, Jacobson EL, Sohn T, Warren D, Emert R, Giordano M. In vivo assessment of antiviral reactivity in chronic HIV infection. HIV Clin Trials. 2000 Nov-Dec;1(3):16-22.

Lalezari JP, Beal JA, Ruane PJ, Cohen CJ, Jacobson EL, Sundin D, Leong WP, Raffanti SP, Wheeler DA, Anderson RD, Keiser P, Schrader SR, Goodgame JC, Steinhart CR, Murphy RL, Wolin MJ, Smith KA. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV patients: a randomized controlled trial. HIV Clin Trials. 2000 Nov-Dec;1(3):1-15.

Smith KA, Jacobson EL, Emert R, Giordano M, Kovacs E, Mumneh N, Pilaro F, Sohn T, Warren D. Restoration of immunity with interleukin-2 therapy.AIDS Read. 1999 Nov;9(8):563-72.

Jacobson EL, Pilaro F, Smith KA Interleukin-2 infusions in HIV-infected patients.N Engl J Med. 1997 Apr 24;336(17):1260-1.

Jacobson EL, Pilaro F, Smith KA Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity.Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10405-10.

Glesby MJ, Bassett R, Alston-Smith B, Fichtenbaum C, Jacobson EL, Brass C, Owens S, Sulkowski M, Race EM, Sherman KE; AIDS Clinical Trials Group A5088 Protocol Team. Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection. J Infect Dis. 2005 Mar 1;191(5):686-93. Epub 2005 Jan 26

Back to topBack To Top